OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Mariana Paes Dias, Sarah C. Moser, Shridar Ganesan, et al.
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 12, pp. 773-791
Closed Access | Times Cited: 359
Mariana Paes Dias, Sarah C. Moser, Shridar Ganesan, et al.
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 12, pp. 773-791
Closed Access | Times Cited: 359
Showing 1-25 of 359 citing articles:
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Yue Zhou, Lei Tao, Jiahao Qiu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 148
Yue Zhou, Lei Tao, Jiahao Qiu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 148
Targeting mutations in cancer
Michael R. Waarts, Aaron J. Stonestrom, Young C. Park, et al.
Journal of Clinical Investigation (2022) Vol. 132, Iss. 8
Open Access | Times Cited: 146
Michael R. Waarts, Aaron J. Stonestrom, Young C. Park, et al.
Journal of Clinical Investigation (2022) Vol. 132, Iss. 8
Open Access | Times Cited: 146
Nanomaterials in tumor immunotherapy: new strategies and challenges
Xudong Zhu, Shenglong Li
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 110
Xudong Zhu, Shenglong Li
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 110
Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial
Jean‐Sébastien Frenel, J.W. Kim, Nanda Aryal, et al.
Annals of Oncology (2022) Vol. 33, Iss. 10, pp. 1021-1028
Open Access | Times Cited: 104
Jean‐Sébastien Frenel, J.W. Kim, Nanda Aryal, et al.
Annals of Oncology (2022) Vol. 33, Iss. 10, pp. 1021-1028
Open Access | Times Cited: 104
DNA damage response revisited: the p53 family and its regulators provide endless cancer therapy opportunities
Yasser Abuetabh, Hong Wu, Chengsen Chai, et al.
Experimental & Molecular Medicine (2022) Vol. 54, Iss. 10, pp. 1658-1669
Open Access | Times Cited: 104
Yasser Abuetabh, Hong Wu, Chengsen Chai, et al.
Experimental & Molecular Medicine (2022) Vol. 54, Iss. 10, pp. 1658-1669
Open Access | Times Cited: 104
Small molecule inhibitors targeting the cancers
Guihong Liu, Tao Chen, Xin Zhang, et al.
MedComm (2022) Vol. 3, Iss. 4
Open Access | Times Cited: 89
Guihong Liu, Tao Chen, Xin Zhang, et al.
MedComm (2022) Vol. 3, Iss. 4
Open Access | Times Cited: 89
Radiation-induced tumor immune microenvironments and potential targets for combination therapy
Siyu Guo, Yihan Yao, Yang Tang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 69
Siyu Guo, Yihan Yao, Yang Tang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 69
A new wave of innovations within the DNA damage response
Qi Li, Wenyuan Qian, Yang Zhang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 56
Qi Li, Wenyuan Qian, Yang Zhang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 56
Drug resistance in ovarian cancer: from mechanism to clinical trial
Ling Wang, Xin Wang, Xueping Zhu, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 54
Ling Wang, Xin Wang, Xueping Zhu, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 54
STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer
Liya Ding, Qiwei Wang, Antons Martincuks, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 1, pp. e005627-e005627
Open Access | Times Cited: 52
Liya Ding, Qiwei Wang, Antons Martincuks, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 1, pp. e005627-e005627
Open Access | Times Cited: 52
A Comprehensive Review of Small Interfering RNAs (siRNAs): Mechanism, Therapeutic Targets, and Delivery Strategies for Cancer Therapy
Jiaying Zhang, Bo Chen, Chunyuan Gan, et al.
International Journal of Nanomedicine (2023) Vol. Volume 18, pp. 7605-7635
Open Access | Times Cited: 49
Jiaying Zhang, Bo Chen, Chunyuan Gan, et al.
International Journal of Nanomedicine (2023) Vol. Volume 18, pp. 7605-7635
Open Access | Times Cited: 49
Revolutionizing DNA repair research and cancer therapy with CRISPR–Cas screens
Samah W. Awwad, Almudena Serrano-Benítez, John C. Thomas, et al.
Nature Reviews Molecular Cell Biology (2023) Vol. 24, Iss. 7, pp. 477-494
Closed Access | Times Cited: 48
Samah W. Awwad, Almudena Serrano-Benítez, John C. Thomas, et al.
Nature Reviews Molecular Cell Biology (2023) Vol. 24, Iss. 7, pp. 477-494
Closed Access | Times Cited: 48
DNA double-strand break–capturing nuclear envelope tubules drive DNA repair
Mitra Shokrollahi, Mia Stanić, Anisha Hundal, et al.
Nature Structural & Molecular Biology (2024) Vol. 31, Iss. 9, pp. 1319-1330
Closed Access | Times Cited: 22
Mitra Shokrollahi, Mia Stanić, Anisha Hundal, et al.
Nature Structural & Molecular Biology (2024) Vol. 31, Iss. 9, pp. 1319-1330
Closed Access | Times Cited: 22
Mechanism-based design of agents that selectively target drug-resistant glioma
Kingson Lin, Susan E. Gueble, Ranjini K. Sundaram, et al.
Science (2022) Vol. 377, Iss. 6605, pp. 502-511
Open Access | Times Cited: 67
Kingson Lin, Susan E. Gueble, Ranjini K. Sundaram, et al.
Science (2022) Vol. 377, Iss. 6605, pp. 502-511
Open Access | Times Cited: 67
Elaiophylin triggers paraptosis and preferentially kills ovarian cancer drug-resistant cells by inducing MAPK hyperactivation
Guannan Li, Xuejiao Zhao, Zhen Wang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 67
Guannan Li, Xuejiao Zhao, Zhen Wang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 67
Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps
Mariana Paes Dias, Vivek Tripathi, Ingrid van der Heijden, et al.
Molecular Cell (2021) Vol. 81, Iss. 22, pp. 4692-4708.e9
Open Access | Times Cited: 66
Mariana Paes Dias, Vivek Tripathi, Ingrid van der Heijden, et al.
Molecular Cell (2021) Vol. 81, Iss. 22, pp. 4692-4708.e9
Open Access | Times Cited: 66
BRCA1-Dependent and Independent Recruitment of PALB2–BRCA2–RAD51 in the DNA Damage Response and Cancer
Tzeh Keong Foo, Bing Xia
Cancer Research (2022) Vol. 82, Iss. 18, pp. 3191-3197
Open Access | Times Cited: 40
Tzeh Keong Foo, Bing Xia
Cancer Research (2022) Vol. 82, Iss. 18, pp. 3191-3197
Open Access | Times Cited: 40
A PARP1 PROTAC as a novel strategy against PARP inhibitor resistance via promotion of ferroptosis in p53-positive breast cancer
Ge Li, Shanshan Lin, Zelei Yu, et al.
Biochemical Pharmacology (2022) Vol. 206, pp. 115329-115329
Closed Access | Times Cited: 40
Ge Li, Shanshan Lin, Zelei Yu, et al.
Biochemical Pharmacology (2022) Vol. 206, pp. 115329-115329
Closed Access | Times Cited: 40
Targeting polyploid giant cancer cells potentiates a therapeutic response and overcomes resistance to PARP inhibitors in ovarian cancer
Xudong Zhang, Jun Yao, Xiaoran Li, et al.
Science Advances (2023) Vol. 9, Iss. 29
Open Access | Times Cited: 40
Xudong Zhang, Jun Yao, Xiaoran Li, et al.
Science Advances (2023) Vol. 9, Iss. 29
Open Access | Times Cited: 40
Mild photothermal therapy boosts nanomedicine antitumor efficacy by disrupting DNA damage repair pathways and modulating tumor mechanics
Yuxuan Xiong, Wei Wang, Qingyuan Deng, et al.
Nano Today (2023) Vol. 49, pp. 101767-101767
Closed Access | Times Cited: 39
Yuxuan Xiong, Wei Wang, Qingyuan Deng, et al.
Nano Today (2023) Vol. 49, pp. 101767-101767
Closed Access | Times Cited: 39
Interferon-ε is a tumour suppressor and restricts ovarian cancer
Zoe R. C. Marks, Nicole K. Campbell, Niamh E. Mangan, et al.
Nature (2023) Vol. 620, Iss. 7976, pp. 1063-1070
Closed Access | Times Cited: 37
Zoe R. C. Marks, Nicole K. Campbell, Niamh E. Mangan, et al.
Nature (2023) Vol. 620, Iss. 7976, pp. 1063-1070
Closed Access | Times Cited: 37
Inhibition of USP7 induces p53-independent tumor growth suppression in triple-negative breast cancers by destabilizing FOXM1
Jingjie Yi, Huan Li, Bo Chu, et al.
Cell Death and Differentiation (2023) Vol. 30, Iss. 7, pp. 1799-1810
Open Access | Times Cited: 31
Jingjie Yi, Huan Li, Bo Chu, et al.
Cell Death and Differentiation (2023) Vol. 30, Iss. 7, pp. 1799-1810
Open Access | Times Cited: 31
Mechanism of PARP inhibitor resistance and potential overcoming strategies
Xiaoyu Fu, Ping Li, Qi Zhou, et al.
Genes & Diseases (2023) Vol. 11, Iss. 1, pp. 306-320
Open Access | Times Cited: 29
Xiaoyu Fu, Ping Li, Qi Zhou, et al.
Genes & Diseases (2023) Vol. 11, Iss. 1, pp. 306-320
Open Access | Times Cited: 29
Poly (ADP-Ribose) polymerase 1 and parthanatos in neurological diseases: From pathogenesis to therapeutic opportunities
Xiaoxue Xu, Bowen Sun, Chuansheng Zhao
Neurobiology of Disease (2023) Vol. 187, pp. 106314-106314
Open Access | Times Cited: 28
Xiaoxue Xu, Bowen Sun, Chuansheng Zhao
Neurobiology of Disease (2023) Vol. 187, pp. 106314-106314
Open Access | Times Cited: 28
Biological effects and mechanisms of fisetin in cancer: a promising anti-cancer agent
Chenhui Zhou, Yi Huang, Sheng Nie, et al.
European journal of medical research (2023) Vol. 28, Iss. 1
Open Access | Times Cited: 26
Chenhui Zhou, Yi Huang, Sheng Nie, et al.
European journal of medical research (2023) Vol. 28, Iss. 1
Open Access | Times Cited: 26
